On June 20, 2025, Replimune Group (REPL, Financial) saw a significant development as Cantor Fitzgerald initiated coverage on the stock with an "Overweight" rating. This marks a noteworthy update for investors keeping a close watch on the biotechnology company.
The analyst responsible for this coverage initiation is Li Watsek, who is associated with Cantor Fitzgerald. The rating of "Overweight" suggests a positive outlook from the analyst, indicating that the stock is expected to perform better than the overall market.
Although there is no specific price target set by the analyst at this time, the "Overweight" rating implies potential confidence in Replimune Group's (REPL, Financial) future performance and growth prospects. Investors will likely keep an eye on further updates and detailed analyses to better inform their investment decisions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Replimune Group Inc (REPL, Financial) is $22.71 with a high estimate of $31.00 and a low estimate of $17.00. The average target implies an upside of 139.35% from the current price of $9.49. More detailed estimate data can be found on the Replimune Group Inc (REPL) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Replimune Group Inc's (REPL, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
